Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia
- PMID: 22650321
- PMCID: PMC3478186
- DOI: 10.1186/1471-2334-12-126
Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia
Abstract
Background: Although the prevalence of macrolide-resistant Mycoplasma pneumoniae isolates in Japanese pediatric patients has increased rapidly, there have been no reports concerning macrolide-resistant M. pneumoniae infection in adolescents aged 16 to 19 years old. The purpose of this study was to clarify the prevalence and clinical characteristics of macrolide-resistant M. pneumoniae in adolescent patients with community-acquired pneumonia.
Methods: A total of 99 cases with M. pneumoniae pneumonia confirmed by polymerase chain reaction (PCR) and culture were analyzed. Forty-five cases were pediatric patients less than 16 years old, 26 cases were 16 to 19-year-old adolescent patients and 28 cases were adult patients. Primers for domain V of 23S rRNA were used and DNA sequences of the PCR products were compared with the sequence of an M. pneumoniae reference strain.
Results: Thirty of 45 pediatric patients (66%), 12 of 26 adolescent patients (46%) and seven of 28 adult patients (25%) with M. pneumoniae pneumonia were found to be infected with macrolide-resistant M. pneumoniae (MR patients). Although the prevalence of resistant strains was similar in pediatric patients between 2008 and 2011, an increase in the prevalence of resistant strains was observed in adolescent patients. Among 30 pediatric MR patients, 26 had an A-to-G transition at position 2063 (A2063G) and four had an A-to-G transition at position 2064 (A2064G). In 12 adolescent MR patients, 10 showed an A2063G transition and two showed an A2064G transition, and in seven adult MR patients, six showed an A2063G transition and one showed an A2064G transition.
Conclusions: The prevalence of macrolide-resistant M. pneumoniae is high among adolescent patients as well as pediatric patients less than 16-years old. To prevent outbreaks of M. pneumoniae infection, especially macrolide-resistant M. pneumoniae, in closed populations including among families, in schools and in university students, physicians should pay close attention to macrolide-resistant M. pneumoniae.
Figures
Similar articles
-
[Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China].Zhonghua Jie He He Hu Xi Za Zhi. 2013 Dec;36(12):954-8. Zhonghua Jie He He Hu Xi Za Zhi. 2013. PMID: 24503430 Chinese.
-
Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.Antimicrob Agents Chemother. 2008 Jan;52(1):348-50. doi: 10.1128/AAC.00779-07. Epub 2007 Oct 22. Antimicrob Agents Chemother. 2008. PMID: 17954691 Free PMC article.
-
Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009.Pediatr Infect Dis J. 2013 Mar;32(3):237-40. doi: 10.1097/INF.0b013e31827aa7bd. Pediatr Infect Dis J. 2013. PMID: 23114374
-
Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia.J Infect Chemother. 2010 Apr;16(2):78-86. doi: 10.1007/s10156-009-0021-4. Epub 2010 Jan 22. J Infect Chemother. 2010. PMID: 20094751 Review.
-
Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance.Clin Respir J. 2017 Jul;11(4):419-429. doi: 10.1111/crj.12379. Epub 2015 Oct 13. Clin Respir J. 2017. PMID: 26365811 Review.
Cited by
-
Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy.Antimicrob Agents Chemother. 2013 Oct;57(10):5181-5. doi: 10.1128/AAC.00737-13. Epub 2013 Jul 29. Antimicrob Agents Chemother. 2013. PMID: 23896480 Free PMC article.
-
Clinical Efficacy of Doxycycline for Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children.Antibiotics (Basel). 2021 Feb 17;10(2):192. doi: 10.3390/antibiotics10020192. Antibiotics (Basel). 2021. PMID: 33671151 Free PMC article.
-
Macrolide Resistance and Its Impacts on M. Pneumoniae Pneumonia in Children: Comparison of Two Recent Epidemics in Korea.Allergy Asthma Immunol Res. 2017 Jul;9(4):340-346. doi: 10.4168/aair.2017.9.4.340. Allergy Asthma Immunol Res. 2017. PMID: 28497921 Free PMC article.
-
Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1505-1522. doi: 10.1007/s10096-025-05101-z. Epub 2025 Mar 19. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40106136
-
Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.Emerg Infect Dis. 2020 Jul;26(7):1382-1391. doi: 10.3201/eid2607.200017. Emerg Infect Dis. 2020. PMID: 32568052 Free PMC article.
References
-
- The committee for the Japanese Respiratory Society guidelines in management of respiratory infections. The Japanese Respiratory Society guideline for the management of community-acquired pneumonia in adults. Respirology. 2006;11(Suppl 3):79–133. - PubMed
-
- National Institute of Health. Infectious Disease Surveillance Center. Mycoplasma pneumoniae pneumonia. 2000. http://idsc.nih.go.jp/idwr/kanja/weeklygraph/18myco.html
-
- Rasmussen JN, Voldstedlund M, Andersen RL, Ellermann-Eriksen S, Jensen TG, Johansen HK, Kolmos B, Molvadgaard M, Nielsen SS, Olsen E, Schonning K, Uldum SA. Increased incidence ofMycoplasma pneumoniaeinfections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill. 2010;15:45. - PubMed
-
- Chalker V, Stocki T, Mentasti M, Fleming D, Harrison T. Increased incidence ofMycoplasma pneumoniaeinfection in England and Wales in 2010: multiocus variable number tandem repeat analysis typing and macrolide susceptibility. Euro Surveill. 2011;16:19. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
